China Biologic Products Holdings, Inc. (CBPO) News
Filter CBPO News Items
CBPO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CBPO News Highlights
- CBPO's 30 day story count now stands at 2.
- Over the past 22 days, the trend for CBPO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CBPO News From Around the Web
Below are the latest news stories about China Biologic Products Holdings Inc that investors may wish to consider to help them evaluate CBPO as an investment opportunity.
China Biologic Announces Completion of Going Private TransactionChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger Sub"), a wholly owned subsidiary of CBPO Holdings Limited ("Parent"), pursuant to the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement") among the Company, Parent and Merger Sub. As a result of the Merger, the Company became a wholly owned subsidiary of Parent and will cease to be a publicly traded company. |
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. |
10 Best Hong Kong Stocks To Buy For 2021In this article, we discussed Chinese billionaire Zhang Lei’s investment philosophy and his 10 best Hong Kong stocks to buy for 2021. Click to skip ahead and see 5 Best Hong Kong Stocks To Buy for 2021. Hillhouse Capital Group founder and Chinese billionaire Zhang Lei has generated strong returns over the years amid his […] |
China Biologic Announces Shareholders' Approval of Merger AgreementChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent (the "Merger"), the plan of merger (the "Plan of Merger") required to be filed with the Reg... |
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data ReadoutHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDA... |
China Biologic Announces Extraordinary General Meeting of ShareholdersChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has called an extraordinary general meeting of shareholders (the "EGM") to be held on March 1, 2021 at 10:00 a.m. (Beijing time), at the principal office of the Company located at 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing, China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), the plan of merger required to be filed... |
Is CBPO A Good Stock To Buy Now?The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […] |
China Biologic Products Must-See Earnings Estimates for: Stock market Insights & financial analysisChina Biologic Products announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by… |
Global Plasma Protein Therapeutics Market Growth, Trends, and Forecasts 2020-2025: Key Players are Takeda Pharma, Octapharma, Grifols, CSL Behring, Biotest, Baxter, and China Biologic Products - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)--The "Plasma Protein Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The plasma protein therapeutics market studied has been projected to grow with a CAGR of nearly 5.3% over the forecast period The major factor attributing to the growth of the market is increasing prevalence of immune deficiency disorders, autoimmune disorders, neurological and bleeding disorders. In addition, the rise in ger |
China Biologic Products (NASDAQ:CBPO) Rating Increased to Hold at BidaskClubChina Biologic Products (NASDAQ:CBPO) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday, BidAskClub reports. Separately, Zacks Investment Research downgraded China Biologic Products from a “buy” rating to a “hold” rating in a research report on Monday, June 22nd. Shares of […] |